冠心病伴抑郁患者抗抑郁治疗安全性的现状与进展  

Safety of antidepressant treatment of coronary heart disease accompanied with depression

作　　者：姜明明[1] 史冬梅[1] 

机构地区：[1]首都医科大学北京安贞医院心内科,北京100029

出　　处：《中国实用内科杂志》2009年第12期1147-1149,共3页Chinese Journal of Practical Internal Medicine

摘　　要：心血管疾病目前已成为人类死亡的首位原因。在众多冠心病危险因素中,抑郁已经被确定为影响冠心病预后的独立危险因子。冠心病患者伴有重症抑郁时,心绞痛的发作显著增加,生活质量恶化,病死率将增加3～5倍。但由于大多数抗抑郁药物对心血管疾病有药物不良反应,使得冠心病伴抑郁患者没有得到应有的抗抑郁治疗。因此对于伴有抑郁的冠心病患者,还需要更多的研究来阐明抗抑郁药物对心血管疾病的药物安全性。Cardiovascular disease has become the first cause of human death. Among the many risk factors in coronary heart disease, depression has been identified as an independent prognostic risk factors. In patients with coronary heart disease accompanied by severe depression,the onset of angina,quality of life deterioration and the mortality will increase by 3 - 5 times. However, the majority of antidepressant drugs have adverse effects on cardiovascular disease adverse drug reactions, making coronary heart disease patients with depression, did not receive antidepressant treatment due. So more researches to clarify the anti-depressant drugs, safety for cardiovascular disease are needed.

关 键 词：冠心痛 抑郁 抗抑郁治疗 

分 类 号：R5[医药卫生—内科学]